Analytical method validation is documented proof, through laboratory studies, that a procedure's performance characteristics meet the requirements of its intended use, before that method is ever used to release or reject a batch. Every batch release decision, stability conclusion and OOS investigation depends on the reliability of the method producing the result.

This course explains what method validation is and why it exists under 21 CFR 211.194(a)(2) and ICH Q2(R2), finalized November 2023. The eight validation parameters are covered in full: specificity, accuracy, precision, detection limit, quantitation limit, linearity, range and robustness.

Full validation, partial validation and verification are explained as distinct, scoped responses to different situations, from a newly developed method through a small parameter change to a compendial method under USP <1226>. Forced degradation study design is covered in depth, including the target 5 to 20 percent degradation range and the risks of both under- and over-stressing a sample.

Method transfer requirements between laboratories are explained, along with ICH Q14's role in method development and Analytical Quality by Design. The course closes with the most common FDA findings in validation programmes, illustrated by a real warning letter case involving missing reference standard traceability documentation.

Five knowledge-check scenarios test real judgment calls: skipping specificity based on assumed degradation history, treating a wavelength change as requiring no assessment, over-stressed forced degradation, method transfer without a comparative study, and why reference standard traceability is foundational rather than administrative.

Built from ICH Q2(R2) 2023, ICH Q14, 21 CFR 211.194(a)(2), USP <1225> and <1226>, and FDA Guidance March 2024.